Overview

A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Status:
Completed

Trial end date:
2020-11-25

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to assess the safety and tolerability of multiple doses of buprenorphine/naloxone alone and buprenorphine/naloxone in combination with a single dose of ASP8062. This study will also assess the potential for pharmacokinetic interaction between ASP8062 and buprenorphine/naloxone.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Collaborator:

National Institute on Drug Abuse (NIDA)

Treatments:

Buprenorphine
Buprenorphine, Naloxone Drug Combination
Naloxone